Want to see TRAW full AI Analyst Report?
TRAW Stock Chart & Stats
$1.25
-$0.87(-9.63%)
At close: 4:00 PM EST
$1.25
-$0.87(-9.63%)
Day’s Range― - ―
52-Week Range$0.64 - $3.27
Previous CloseN/A
Volume35.69K
Average Volume (3M)206.36K
Market Cap
$10.28M
Enterprise Value$4.17M
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding15,228,328
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-14.78
Price to Sales (P/S)3.33
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue1.52
Enterprise Value/Gross Profit1.52
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$1.00Price Target Upside-20.00% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No DebtAbsence of debt eliminates interest expense and refinancing risk, preserving financial flexibility while Traws advances long clinical timelines. For a cash-burning clinical-stage biotech, a debt-free capital structure reduces solvency pressure and lowers immediate default risk during development cycles.
Established Equity Financing ChannelsAccess to a PIPE plus an At-The-Market program and shelf registration provides recurring, milestone-linked equity capacity that extended runway into early 2027. This flexible funding capability supports execution of clinical milestones without reliance on a single large raise, which is durable for near-term development.
Broad-spectrum Pipeline & PartnershipsProgress on a host‑targeted broad‑spectrum antiviral and formal collaborations for outbreak response and local manufacturing position Traws in pandemic preparedness markets. Strategic partnerships and scaling plans for supply/registration increase real-world applicability and long-term market relevance.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow have been consistently negative, with a major deterioration in 2025; reported net income did not translate to cash. Chronic cash burn forces ongoing external financing, heightening dilution risk and limiting ability to invest organically or absorb development delays.
Negative EquityNegative shareholders' equity in 2025 signals accumulated losses or write-downs that erode balance sheet resilience. This condition restricts financial flexibility, complicates lender/partner assessments, and increases reliance on dilutive equity issuances to fund clinical programs over the medium term.
Regulatory Execution RiskA negative MHRA review deferred the planned Phase 2a influenza challenge trial and the company is addressing additional toxicology requests while managing a U.S. FDA IND hold. These regulatory setbacks materially risk timelines, increase development costs, and can delay value‑creating readouts.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.64 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $10.28M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on May 15, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.56 by $0.03.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Overvalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -0.34.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 15,228,328 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.56. Following the earnings report the stock price went up 15.337%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
TRAW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.View all TRAW earnings summariesTRAW Stock 12 Month Forecast
Average Price Target
$1.00
▼(-20.00% Downside)
Technical Analysis
Ownership Overview
12.49% Insiders
0.74% Mutual Funds
20.83% Other Institutional Investors
65.57% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---